Welcome to our dedicated page for TruBridge SEC filings (Ticker: TBRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TruBridge, Inc. (NASDAQ: TBRG) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, drawn in real time from the EDGAR system and supported by AI-powered analysis. TruBridge is a healthcare technology and solutions company focused on rural and community hospitals and providers, and its filings offer detailed insight into how it reports financial performance, manages risk, and governs its operations.
Key documents for TruBridge include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company presents audited and interim financial statements, segment information for its Financial Health and Patient Care business units, and discussions of risk factors and internal control over financial reporting. For example, TruBridge has disclosed material weaknesses related to revenue processes and customer contract changes in prior years, and it has reported on changes to its independent registered public accounting firm, including the dismissal of Grant Thornton LLP and engagement of KPMG LLP.
Current reports on Form 8-K capture material events such as quarterly earnings releases, leadership changes, board refreshment actions, cooperation agreements with major shareholders, and financing developments like the 2025 Amended and Restated Credit Agreement with its lending partners. These filings help investors understand how TruBridge is addressing governance, capital structure, and strategic priorities in the context of rural and community healthcare.
On this page, users can review TruBridge’s Forms 10-K and 10-Q, 8-Ks describing significant corporate events, and other exhibits referenced in those reports. AI-generated summaries highlight the main points of each filing, explain complex accounting or control matters in plain language, and surface items related to revenue cycle management, EHR and patient engagement operations, internal control conclusions, and auditor changes. Filings related to executive and director arrangements, such as severance agreements and board appointments, are also accessible, along with any associated exhibits.
By using these tools, readers can quickly understand what TruBridge reports to regulators about its financial health, operational segments, governance, and risk profile, without having to parse every line of the underlying documents themselves.
TruBridge, Inc. has been acquired and taken private by Inventurus Knowledge Solutions, Inc. (IKS Health). On July 9, 2026, Merger Sub was merged into TruBridge, which now operates as a wholly owned subsidiary of the buyer.
At the merger effective time, each share of TruBridge common stock (other than excluded and appraisal shares) was converted into the right to receive $26.25 per share in cash, without interest. In connection with closing, TruBridge repaid in full and terminated its existing Amended and Restated Credit Agreement, including all related guarantees and liens.
The acquirer funded the deal through $635.0 million of senior secured credit facilities. TruBridge requested Nasdaq delist its common stock, which ceased trading before the July 9, 2026 market open, and the company plans to deregister the shares and suspend its SEC reporting obligations following effectiveness of a Form 25 and subsequent Form 15 filing.
TruBridge, Inc. submitted a Form 25 notification via Nasdaq to remove its Common Stock from listing and withdraw its registration on the Nasdaq Stock Market LLC.
The exchange certifies it has complied with 17 CFR 240.12d2-2 and the issuer has complied with the Exchange rules governing voluntary withdrawal.
TruBridge, Inc. stockholders approved its planned merger with Inventurus Knowledge Solutions, Inc. at a special meeting held July 7, 2026. The merger will combine TruBridge with IKS Next Horizon, Inc., making TruBridge a wholly owned subsidiary of Inventurus Knowledge Solutions, Inc.
Of 14,999,136 shares outstanding as of the record date, 11,334,144 shares (about 75.6%) were represented, providing a quorum. The merger proposal passed with 11,305,399 votes for, 8,818 against and 19,927 abstaining. Stockholders also approved, on a non-binding advisory basis, merger-related compensation for named executive officers.
The company expects the merger to close on July 9, 2026, subject to remaining customary conditions. After closing, TruBridge common stock is expected to be delisted from the Nasdaq Global Select Market, and no stockholders exercised appraisal rights in connection with the transaction.
TruBridge, Inc Schedule 13G/A amendment states that Camac Fund directly held 404,743 shares of Common Stock as of June 30, 2026, representing 2.7% of the class. The filing bases percentages on 14,999,136 shares outstanding as of May 5, 2026.
The filing lists Camac Partners, Camac Capital, Camac Fund, and Eric Shahinian as reporting persons and shows shared voting and dispositive power over the disclosed shares. Ownership is reported under the Schedule 13G/A framework.
TruBridge, Inc. reported that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its planned merger with Inventurus Knowledge Solutions’ affiliate expired on June 22, 2026, allowing the transaction to move past this key U.S. antitrust review step.
The company still must satisfy other closing conditions in the Merger Agreement, including approval of the deal by holders of a majority of TruBridge common shares entitled to vote. TruBridge has mailed a definitive proxy statement to stockholders and urges them to review it before voting on the proposed merger.
TruBridge, Inc. is asking stockholders to approve a proposed cash acquisition by Inventurus Knowledge Solutions, Inc. (IKS) under an Agreement and Plan of Merger dated April 23, 2026. If approved, holders of eligible TruBridge common stock will receive $26.25 in cash per share at the Effective Time.
The Board unanimously recommends approval and TruBridge solicited voting agreements covering 4,094,178 shares (approximately 27.3% of outstanding voting power as of June 2, 2026). The proxy discloses expected financing arrangements, termination fees, appraisal rights, required stockholder vote thresholds, and Nasdaq delisting and deregistration steps post-closing.
TruBridge, Inc. is soliciting proxies for a virtual special meeting to approve an Agreement and Plan of Merger dated April 23, 2026, under which Inventurus Knowledge Solutions, Inc. (IKS) will acquire TruBridge. Each eligible share will entitle holders to $26.25 in cash at the Effective Time.
The Board unanimously recommends a vote FOR the Merger Proposal and the advisory Named Executive Officer Merger-Related Compensation Proposal. The Merger is subject to customary closing conditions, HSR review and financing; IKS and financing sources expect to provide the funds needed to complete the transaction.
TruBridge, Inc. Schedule 13G filed reporting that Glazer Capital, LLC and Paul J. Glazer beneficially own 804,987 shares of Common Stock, representing 5.37% of the class. The filing states the shares are held by Glazer-managed funds with shared voting and dispositive power.
TruBridge, Inc. reported first-quarter 2026 results and highlighted its pending cash acquisition by IKS Health. Under the definitive agreement, TruBridge shareholders will receive $26.25 in cash per common share, with closing expected in the third calendar quarter of 2026, subject to shareholder and regulatory approvals.
For the quarter ended March 31, 2026, TruBridge generated $86.3 million in revenue versus $87.2 million a year earlier. GAAP net income was $0.5 million, or $0.03 per diluted share, compared with $0.5 million and the same per-share result in 2025. Non-GAAP net income rose to $8.5 million, driving non-GAAP EPS of $0.59 versus $0.36.
Adjusted EBITDA was $16.5 million compared with $18.2 million a year ago. Cash and cash equivalents increased to $35.4 million from $24.9 million at year-end 2025, supported by $15.5 million of net cash provided by operating activities. Total bookings on an annual contract value basis were $17.7 million, slightly above the prior-year quarter.